Annexon announces clinical and regulatory progress for anx005 pivotal program in guillain-barrÉ syndrome (gbs)

Anx005 granted orphan drug designation by the european medicines agency for the treatment of gbs target enrollment achieved in phase 3 pivotal study of anx005 in gbs representing the company's third successfully executed clinical study in gbs company on track to report pivotal data in the first half of 2024 brisbane, calif., oct. 10, 2023 (globe newswire) -- annexon, inc. (nasdaq: annx) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that the european medicines agency (ema) granted orphan drug designation to anx005 for the treatment of guillain-barrÉ syndrome (gbs).
ANNX Ratings Summary
ANNX Quant Ranking